Which pathway addresses muscle loss (sarcopenia)?
Muscle loss is routed by hormonal context. Men with confirmed low testosterone → TRT. Peri/menopausal women → BHRT (often with low-dose testosterone). GH-axis decline → sermorelin. Resistance training and protein remain foundational.
Full answer
Sarcopenia and accelerated lean-mass loss are routed by hormonal context. Resistance training and protein intake (≥1.6 g/kg) remain foundational regardless of pathway. Men with confirmed low testosterone whose lean-mass loss matches biomarker context are evaluated for Testosterone Optimization. Peri/menopausal women with matching biomarkers are evaluated for BHRT, sometimes including low-dose testosterone. Candidates with documented GH-axis decline are evaluated for sermorelin. Every initiation is synchronous-video provider-reviewed.
Educational. Not a substitute for individualized provider review.
- Testosterone Optimization pathway — Primary source · oMeds
- Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-05-29